Skip to Main Navigation Skip to Content

Full Prescribing Information

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women whose disease has returned or progressed following antiestrogen therapy. To learn more download the Prescribing Information for FASLODEX.

To view the download, you need Adobe^® Acrobat^® Reader^® installed. If you do not have Adobe Acrobat Reader on your computer, you can download it from the Adobe Web site.

Adobe Acrobat Reader is a registered trademark of Adobe Systems Incorporated.

Important Information About FASLODEX (fulvestrant) Injection

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women whose disease has returned or progressed following antiestrogen therapy.

Important Safety Information about FASLODEX

Prescription FASLODEX is only for postmenopausal women. Do not take FASLODEX if you are pregnant and do not become pregnant while taking FASLODEX because it may harm your unborn child. (See WARNINGS and CONTRAINDICATIONS sections of full Prescribing Information.)

Because FASLODEX is administered intramuscularly, it should not be used in patients with certain blood disorders or in patients receiving anticoagulants (sometimes called blood thinners, for example, warfarin).

In clinical studies, the most commonly reported side effects were nausea, vomiting, constipation, diarrhea, abdominal pain, headache, back pain, hot flashes, sore throat, and injection site reactions with mild, transient pain and inflammation.

Please see full Prescribing Information. For more information, see your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

FASLODEX is a registered trademark of the AstraZeneca group of companies.

This site is intended for US consumers/patients. If you are a non-US consumer/patient, click here.